

# News Highlights

*June 22, 2017*

## **Dr. Charles Rosser wins 'best poster' at American Urological Association Meeting**

Dr. Charles Rosser, associate director of the UH Cancer Center's Translational and Clinical Research, won 'best poster' at an American Urological Association Annual meeting bladder cancer session in Boston, Massachusetts. The poster outlined cancer research for the interleukin-15 (IL-15) agonist complex (ALT-803), in combination with bacillus Calmette-Guérin (BCG). The drug is expected to be effective for patients with non-muscle invasive bladder cancer, the most common type of bladder cancer.

The ALT-803 in combination with BCG received Fast Track designation from the U.S. Food and Drug Administration (FDA). The designation expedites FDA review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need.

"The last time the FDA approved a drug for bladder cancer was almost two decades ago. Bladder cancer treatment hasn't advanced very much, BCG has been the main drug used to treat the disease since the '80s," said Dr. Rosser. "The science field has changed so much since then. We may finally be able to move the field forward and get better drugs to patients."